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BACKGROUND
Malaria is a serious health problem in many of the countries from which refugees come to Australia. Anopheles 
mosquitoes capable of transmitting malaria are present in the far north of Australia and in these areas, the detection 
and appropriate treatment of malaria is vital, not only for the health of the individuals and their families, but as a 
significant public health issue.
OBJECTIVE
This article outlines screening, assessment and management of malaria in the refugee population.
DISCUSSION 
Most malaria does not follow the classic pattern of periodic fever with paroxysms of cold, hot and sweating 
stages. There should be a high index of suspicion for anyone from an endemic area presenting with fever, vomiting, 
diarrhoea, headache and/or muscle pain, even if they have been tested or treated for malaria. What is most likely 
to be a nonspecific viral illness in someone who has never left Australia might be an urgent life threatening illness 
in a recently arrived refugee. Therefore all refugees from endemic areas, whether symptomatic or not, should 
be screened as soon as possible after arrival. Appropriate treatment is expensive and should be monitored by a 
hospital, but can be done as an outpatient in some individuals. Follow up with thick and thin films as a ‘test of cure’ 
should be done at 28 days. 
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Miriam, 2 years of age, came to Australia with her 17 year old Sudanese mother from a Ugandan 
refugee camp. Five days before leaving Africa she was screened for malaria with a rapid 
diagnostic test (RDT). This was reported as negative and so she was not given antimalarials 
before departure. 
Three days after arrival, Miriam’s mother went to a nearby pharmacy to buy some paracetamol as 
Miriam was febrile with vomiting and diarrhoea. The pharmacist called an ambulance as the child 
appeared flat and toxic. She was admitted to an intensive care unit where she had the following 
blood tests: 
• haemoglobin 52 gm/L (101–131) 
• platelets 62 x 109/L (150–450) 
• C-reactive protein (CRP) 214 mg/L (<6) 
• potassium 2.1 mmol/L (3.2–4.5) 
• bilirubin 47 µmol/L (<20), and 
• positive thick and thin films for malaria.
Films showed a parasite density of 24% (ie. 24% of all her red blood cells contained parasites) and 
a mixed Plasmodium falciparum and P. vivax infection. A G6PD screening test was normal. 
Miriam was treated with a blood transfusion as well as intravenous quinine and oral clindamycin 
for 1 week, followed by a 2 week course of oral primaquine. On follow up 1 month later her: 
haemoglobin was 120, platelets 254, potassium 4.6, bilirubin 9, and no malaria parasites were 
detected on thick or thin film.
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Malaria was eradicated from Australia in 
1981,1 although there has since been rare 
locally acquired cases in North Queensland.2 
The disease remains an important cause 
of death and illness in children and adults 
in tropical countries. Forty percent of the 
world’s population is at risk of malaria 
and there are 300–500 million clinical 
cases throughout the world per year.3 The 
worldwide annual death rate of almost 3 
million people has risen in recent years, 
probably due to the increasing resistance to 
medication, and 89% of these deaths occur 
in Africa.3–5 Of the approximately 13 000 
refugees who arrive in Australia each year, 
about 70% come from areas where malaria 
is a major health problem. For example, 
in Sudan and Uganda, the countries of 
origin or transit of the majority of recently 
arrived refugees, malaria is responsible for 
about 30% of all outpatient attendances 
and about 15% of all deaths.3,6 Malaria also 
occurs in southeast Asia and Pakistan, the 
source countries for many of the non-African 
refugees who come to Australia. 
There are four species of Plasmodium that 
cause human malaria. P. falciparum is the 
cause of nearly all malaria deaths and behaves 
differently in many other respects to P. vivax, P. 
malariae and P. ovale.
Transmission
Malaria is usually transmitted by the Anopheline 
mosquito but can also be transferred directly 
by blood transfusion, transplacentally or by 
accidental inoculation. Anopheles mosquitoes 
are still present above latitude 17–19º S in the 
far north of Australia. In these malaria receptive 
areas, the detection and appropriate treatment 
of malaria is of the utmost importance, not only 
for the health of the individuals and their families, 
but as a significant public health issue.1 Patients 
with malaria in these areas should be treated in 
screened or air conditioned accommodation or 
preferably admitted to hospital.4 There were 47 
notifications of malaria in the Northern Territory 
in 2005 and 66 in 2006, and the Territory’s 
treatment protocols reflect the additional need 
to be aware of the presence of gametocytes.7 
Gametocytes are the ‘sexual’ phase of the 
parasite that can persist in the circulation for 
several weeks and which are infective to the 
mosquito, and hence cause further infection to 
other humans.8 Malaria is a notifiable disease in 
all Australian states and territories.9 
Testing for malaria
Malaria rapid diagnostic tests (RDT), sometimes 
called ‘dipsticks’, detect specific antigens 
produced by the malaria parasites present in the 
blood. Some RDT detect only P. falciparum, while 
others also detect nonfalciparum malaria (P. 
vivax, P. malariae, P. ovale).10 They are generally 
highly sensitive and specific for P. falciparum 
but unreliable for other species and should not 
be used for nonfalciparum species. These tests 
can be done quickly by most laboratories in 
Australia using an EDTA sample (full blood count 
[FBC] collection tube) or finger prick sample.11 If 
the RDT is positive, it should be followed up by 
a thick and thin blood film (also done from an 
EDTA sample), which is still the ‘gold standard’. 
A thick film to detect small numbers of parasites 
and a thin film to identify the species should 
be done regardless of other tests performed. 
An RDT should not be used for follow up as 
antigen may still be present for several weeks 
after the parasites have died. Follow up should 
always be done with thick and thin films. Some 
laboratories may do a polymerase chain reaction 
(PCR) to detect Plasmodium DNA, although this 
is neither validated nor commercially available 
at present. 
Pre-arrival assessment of refugees
The majority of refugees who arrive in Australia 
from Africa have a ‘fitness to fly’ assessment 
that includes a RDT.10 If the test is positive, 
patients are treated with a 3 day course of 
artemether/lumefantrine before they leave the 
country. However, the sensitivity of the test is 
only 95–98%10 and so will miss 2–5% of those 
with malaria, those with early infection, a low 
parasite count, or those who contract infection 
between having the health assessment and 
leaving the country (sometimes up to a week). 
The 3 day treatment is not supervised and often 
not actually taken. This is consistent with figures 
from refugee health services around Australia 
confirming an incidence of malaria of 8% in 
Western Australia,12 5% in South Australia,13 
10% in Hobart,4 and 16% in Newcastle.14 These 
figures were collected before the introduction 
of predeparture screening and treatment for 
malaria. Since this policy change, the incidence 
is less, but a significant number of cases still 
occur and we should not be lulled into a false 
sense of security by the existence of the 
predeparture screening. 
Clinical presentations
Most infections are not as dramatic as Miriam’s 
and are asymptomatic or have minimal 
symptoms.15 Older patients have usually 
developed partial immunity to malaria and may 
not be symptomatic on arrival. However, as their 
immunity wanes, they can potentially become 
ill, sometimes up to several years after arrival in 
Australia, if the parasite is not screened for and 
treated appropriately.16 Children are the most 
vulnerable for sudden and severe infection as 
they have not built up immunity. Other high 
risk groups include pregnant women and 
splenectomised adults. 
 Most malaria seen in refugees to Australia 
does not follow the traditional pattern of periodic 
fever with paroxysms of cold, hot and sweating 
stages. General practitioners should have a high 
index of suspicion of anyone from an endemic 
area with fever, vomiting, diarrhoea, headache 
and/or muscle pain. What is most likely to be 
a nonspecific viral illness in someone who 
has never left Australia might be an urgent life 
threatening illness in a recently arrived refugee. 
Clinical examination might reveal other signs 
of malaria such as splenomegaly, confusion, 
drowsiness, hypotension, oliguria or jaundice. 
Children and pregnant women in particular are 
at risk of becoming very unwell within a very 
short space of time. Altered consciousness in 
those with malaria might be caused by cerebral 
malaria, hypoglycaemia, acidosis or seizures. 
Treatment
Response to treatment can be dramatic, 
particularly with the artemesinin derivatives. 
Treatment options will be influenced by: 
• symptoms 
• species of infection 
• pregnancy status 
• age of patient, and 
• finances. 
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Detailed instructions should be given with an 
interpreter present about dosage regimens, 
side effects, follow up arrangements and the 
symptoms and signs of treatment failure. 
Falciparum malaria
Falciparum malaria is resistant to chloroquine 
and requires more complex treatment than 
nonfalciparum malaria. The newer artemesinin 
based agents are recommended as combination 
therapy for uncomplicated falciparum malaria 
as they: 
• have no significant drug resistance 
• are rapidly effective, and 
• are active against the gametocytes not 
killed by other antimalarials.11,17
The only artemesin based combination therapy 
currently available in Australia is artemether/
lumefantrine (Riamet). The dosing schedule can 
be simplified to a twice daily dosing schedule for 
3 days (total six doses). It is important that the 
medication be taken with fatty food (although a 
biscuit or a glass of milk may be enough). 
 Atovaquone/proguanil  (Malarone) and 
mefloquine (Larium) have shorter treatment 
schedules, however there is occasional 
resistance to these drugs. Furthermore, 
mefloquine cannot be given to those with a 
history of psychiatric illness or epilepsy, and 
can cause vomiting in 5–10%. For this reason 
mefloquine should not be used in recently 
arrived refugees because of a high incidence 
of psychological morbidity such as post-
traumatic stress disorder. Other medications 
such as quinine sulphate and doxycycline are 
rarely used because of increased side effects 
and longer dosing periods.11 
 Current recommendations for Australia 
suggest that all patients with falciparum 
malaria be admitted to hospital.11 However, 
most regions in Australia have local guidelines 
based on outpatient treatment for refugees 
who meet the following criteria: 
• asymptomatic or minimally symptomatic 
infection (not vomiting)
• not pregnant
• weighing >10 kg, and/or >12 months of 
age, and 
• parasitaemia of <1%.7,15 
The treatment of choice for these patients is 
artemether/lumefantrine, which is expensive 
(~$80 per course for a 70 kg adult) and 
should be provided by a hospital pharmacy or 
funded community health centre. The cost of 
atovaquone/proguanil is ~$56 and mefloquine 
is ~$21 per course.15 Outpatient treatment 
of falciparum malaria should be done in close 
association with a hospital, not only for cost 
reasons, but so that expertise and facilities are 
available if urgently required.
 Children weighing <10 kg or <12 months 
of age, pregnant women, those with a 
parasitaemia >1%, and symptomatic patients 
should be urgently admitted to hospital and 
managed as inpatients, preferably by an 
infectious diseases physician or paediatrician. 
Severely i l l  patients or those unable to 
tolerate oral medications will be treated with 
intravenous artesunate. Drugs considered 
safe in pregnant women and children include 
quinine sulphate, chloroquine, proguanil and 
clindamycin. The combination of quinine and 
clindamycin is generally used for pregnant 
women or for children weighing <10–20 kg. 
Artemether/lumefantrine only has marketing 
approval in Australia for those over 12 years 
of age. However, it is safe to use for children 
with a weight down to 20 kg (off label). Dosing 
is given in the latest edition of Therapeutic 
Guidelines: antibiotic.18
Nonfalciparum malaria
Patients with nonfalciparum malaria are 
usually treated as outpatients with 3 days 
of oral chloroquine; although chloroquine 
resistance has developed in parts of Indonesia, 
New Guinea and East Timor.11 For patients 
with mixed infections of falciparum and 
nonfalciparum malaria, any of the treatments 
used for P. falciparum will also kill the active 
(asexual) phase of P. vivax, P. ovale and P. 
malariae. 
 In patients with P. vivax and P. ovale, 
hypnozoites (a dormant phase of the parasite 
in the liver) can cause relapses by reactivating 
for at least 5 years if only chloroquine is given.8 
Primaquine needs to be given for 14 days 
to eradicate the hypnozoites (it also kills the 
gametocytes of all species, although this effect 
is only important in malaria receptive areas).11 
The eradication of hypnozoites to prevent 
future relapses is sometimes called a ‘radical 
cure’. Acute haemolysis can occur in patients 
with glucose-6-phosphate dehydrogenase 
(G6PD) defic iency if  given pr imaquine, 
therefore this should be ruled out before using 
primaquine. Primaquine is also expensive ($60 
for a 14 day course) and is best accessed 
through a hospital pharmacy. 
Follow up
If a patient has symptoms suspicious of malaria 
but negative blood tests, the tests should be 
repeated. Patients treated on an outpatient 
basis should be reviewed daily for 3 days to 
ensure adherence and detect deterioration. If 
they are well and have taken all medications, 
they do not need repeat blood tests until 28 
days. If there was a decreased FBC initially or 
any deterioration, then the FBC and malaria 
films should be repeated at 7 days. All patients 
treated should have a ‘test of cure’ with thick 
and thin films 28 days after commencing therapy 
as recrudescence (parasite numbers decreased 
but not completely eradicated) or relapse may 
occur. If treatment has been successful there 
should be no detectable parasites on a day 28 
blood film. Rapid diagnostic tests may remain 
positive for a month after treatment and are 
not useful for follow up. Treatment failure is 
rare and may be due to drug resistance, the 
patient not completing the course of treatment, 
or poor gastrointestinal absorption, especially 
with atovaquone/proguanil or artemether/
lumefantrine.
Conclusion
Screening and appropriate treatment of all 
refugees who have come from countries 
where malaria is endemic is essential as soon 
as possible after arrival in Australia. Those with 
falciparum malaria, even if asymptomatic, 
can progress rapidly to become severely ill or 
have persistent parasitaemia which can cause 
anaemia or other symptoms many years later.15 
The public health fear of the reintroduction 
of malaria into Australia is another reason to 
be vigilant.1 
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